Free Trial
→ The Robotics Revolution has arrived … and one $7 stock could take off as a result. (From Weiss Ratings) (Ad)
OTCMKTS:ARTH

Arch Therapeutics 5/9/2024 Earnings Report

Arch Therapeutics logo
$0.0012 0.00 (0.00%)
As of 06/13/2025
ProfileEarnings History

Arch Therapeutics EPS Results

Actual EPS
-$0.33
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Arch Therapeutics Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Arch Therapeutics Announcement Details

Quarter
Date
5/9/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Arch Therapeutics' next earnings date is estimated for Monday, August 18, 2025, based on past reporting schedules.

Conference Call Resources

Arch Therapeutics Earnings Headlines

Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
October 1, 2024 | globenewswire.com
Chicago biotech-focused VC firm Arch Venture Partners closes $3 billion fund
September 27, 2024 | bizjournals.com
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
While practically every popular investment has been swinging wildly these past weeks … Gold has been surging to new record highs. And according to Wall Street's biggest banks, this is just the start … Goldman Sachs is telling clients to "buy gold" to protect from the trade wars and economic uncertainty.
June 16, 2025 | Weiss Ratings (Ad)
Arch Therapeutics, Inc. (ARTH)
August 21, 2024 | finance.yahoo.com
Arch Biopartners' Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins
August 2, 2024 | tmcnet.com
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)
May 6, 2024 | globenewswire.com
See More Arch Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arch Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arch Therapeutics and other key companies, straight to your email.

About Arch Therapeutics

Arch Therapeutics (OTCMKTS:ARTH), together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

View Arch Therapeutics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles